Clinical Leaders Session

1. MSD Ireland
Mick Phelan
Business Unit Director

2.  Known as MSD worldwide except in the US and Canada where we are
Merck
 A global healthcare leader working to help the world be well
 The world’s No. 2 healthcare company that operates in
140 countries
 We develop and deliver prescription medicines, vaccines, biologic
therapies, and consumer care and animal health products
 We are committed to increasing access to healthcare through far-
reaching policies, programmes and partnerships to help people around
the world lead healthier lives
MSD across the Globe

3.  We employ over 2,000 people at sites in Dublin, Carlow, Cork,
Tipperary and Wicklow.
 We have invested over €2.2bn in Ireland over the last five
decades
 In 2011 we spent in excess of €400 million on goods and services
in Ireland, thus supporting many other businesses and jobs in the
Irish economy
 In 2012 we contributed €2.3m in support of medical education for
healthcare professionals, for local Irish charities, community and
patient groups, and in our work towards environmental
sustainability
MSD in Ireland

4. Irish Sites

5.  We manufacture or package many of our leading products for the world market
in Ireland – 12 of our global top 20 products are manufactured in Ireland
 Our Irish sites are renowned for their capability to rapidly introduce new
products (and additional volumes of existing products) at minimal additional
capital cost, ensuring supply for new product launches / expanding market
opportunities
 Our Carlow site is a state-of-the-art vaccines and biologics facility, with
ambitious growth plans for its future. It is MSD’s first vaccines facility to be built
outside of the US
 Our Ballydine site currently supports worldwide revenues of approx. €8bn and
focuses on new product R&D commercialisation
Our Manufacturing Presence

6. Our Areas of Focus

7. MSD Partnership in Hospitals
 Longstanding contributions to Education, Patient Programs,
Disease Management, Clinical Staff Support, Health Care
Technology
 Therapeutic focus include Rheumatology, Gastroenterology,
Cardiology, Diabetes, Microbiology, Critical Care and Surgery
 We are focused on understanding the changing environment:
e.g., emergence of Hospital Groups, MFTP and other planned
Health Care Reforms.
 MSD is evolving to reflect these changes and to ensure that we
remain an effective partner for you through the change.

8. MSD is Evolving
 10% reduction through voluntary redundancies Dec 2013
 Refocusing efforts to growth areas and new product launches
(e.g., Infectious Disease, Oncology)
 Resources increased in Market Access, Account Management
and Medical Affairs
 Account Management aligned with Hospital Group structure

9. Hospital Account Managers
Ger Bowens
Niamh McEvoy
Anne Martina Mulligan
• Interact with Hospital Group Management
• Understand the Group, its priorities and ID mutually beneficial
partnership opportunities
• Commercial Negotiations
• Interact with Hospital Group Management
• Understand the Group, its priorities and ID mutually beneficial
partnership opportunities
• Commercial Negotiations

10. MSD Hospital Group Partnership Approach
Partnership opportunities close to our current and pipeline therapeutic areas
Opportunities may be MSD alone or in collaboration with other pharmacy/industry
partners
Focus, at least initially on smaller, short term, patient outcome focused and
measurable initiatives
Large partnership groups with broad, long term, difficult to measure objectives are
less attractive.
We are committed to MSD’s ethical and compliance standards and requirements.
When working with industry partners, recognise that compliance requirements will
differ by company
Partnership engagements may identify potential business development opportunities

11. Thank You www.msd.ie